Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain.
Adeno-associated virus type 2 (AAV2)-based vectors are promising transgene carriers for experimental gene therapy treatments of brain diseases. However, detailed evaluation of transgene distribution, trafficking, and transport within the brain is of the utmost importance before applying any type of gene therapy in humans. We examined the distribution of AAV2-thymidine kinase (AAV2-TK) and AAV2-aromatic L-amino acid decarboxylase (AAV2-AADC) in monkey brain after convection-enhanced delivery (CED). The AADC group consisted of two 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys that received unilateral infusions of AAV2-AADC into six sites in the right hemisphere. The TK group consisted of three monkeys that received bilateral CED infusion of AAV2-TK into the putamen; one side in all three monkeys was coinfused with heparin. Six weeks after AAV delivery, the brains were collected and processed for immunohistochemical staining. Volumetric measurement of TK distribution showed that at least 75% of the putamen could be covered by a single infusion of the vector; however, no effects of heparin coadministration were found, most likely because of the already robust gene transfer achieved by CED. Interestingly, TK- and AADCimmunoreactive cells were also present outside the striatum, in the globus pallidus, subthalamic nucleus, thalamus, and substantia nigra. CED proved to be an efficient method for delivery of the AAV2 vector. Detection of the transgenes in brain structures distant from the site of injection emphasizes the potential for gene transport, and the advantages and disadvantages of CED for gene therapy deserve further study.
Laboratory of Molecular Therapeutics, Neurological Surgery, University of California, San Francisco, San Francisco, CA 94103, USA.
Piotr
P
Hadaczek
Malgorzata
M
Kohutnicka
Michal T
MT
Krauze
John
J
Bringas
Phil
P
Pivirotto
Janet
J
Cunningham
Krystof
K
Bankiewicz
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000008:administration & dosage; D000818:Animals; D001692:Biological Transport; D018481:Convection; D000229:Dependovirus / Q000235:genetics*; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D008253:Macaca mulatta; D008297:Male; D010300:Parkinson Disease / Q000209:etiology / Q000473:pathology / Q000628:therapy; D011699:Putamen / Q000201:enzymology* / Q000473:pathology; D013937:Thymidine Kinase / Q000235:genetics* / Q000378:metabolism; D014162:Transfection; D019076:Transgenes / Q000502:physiology
D006493:Heparin; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D013937:Thymidine Kinase